List view / Grid view
24 September 2020 | By PerkinElmer
During this on-demand webinar, two leading researchers will discuss their innovative approaches to developing novel opportunities for immunotherapy treatments.
Helping in the race to identify effective neutralising antibodies against the spike protein of SARS-CoV-2 virus as the COVID-19 global death rate continues to rise.
Many anti-angiogenic drugs have been developed to use in cancer therapy, while pro-angiogenic molecules may hold potential in regenerative applications.
Molecular Devices helps Recursion produce the largest publicly available set of human cellular morphological data for COVID-19 therapeutic research.
A powerful, yet affordable, high-content imaging system in your own lab.
Discover how you can simplify your workflow by combining microplate reading and imaging in a small footprint.
In human cells, a drug candidate called PF-00835231 has demonstrated success at blocking the reproduction of SARS-CoV-2.
Researchers have developed a molecule that can restore lost connections in the spinal cords and brains of mice with cerebellar ataxia, Alzheimer's disease and spinal cord injury.
By targeting a previously undiscovered allosteric site on a DMD-associated enzyme, researchers found muscle cell conditions improved.
Researchers have revealed that the antibiotic concanamycin A targets a protein called Nef, allowing the immune system to destroy HIV in cells.
Sign up for free weekly 5-10 min videos from Horizon’s expert cell line engineers to help you improve your CRISPR editing experiments.
This webinar explains how synthetic guide RNAs are stable, eliminate cloning and sequencing steps, and avoid innate immune responses and cytotoxicity.
Horizon article on the recipe for success for CRISPR editing in T cells.
This article explains how to plan a gene-editing experiment. How to choose your biological system and what reagents to get for your experimental aim.
Modify the genome and modulate expression of genes within human iPS cells with Dharmacon™ Edit-R CRISPR reagents.
